Up to now, the name BioNTech has popped up mostly in one breath with Pfizer, the company’s US partner in developing the mRNA-based Covid-19 vaccine marketed as Comirnaty...
Pfizer and BioNTech expect to have a modified version of their mRNA-based Covid-19 vaccine ready to tackle the Omicron variant by March, Pfizer CEO Albert Bourla said on...
Between the Christmas and the New Year’s bells and on both sides, the international pharmaceutical and healthcare sector continued battling the coronavirus pandemic. In...
With the fast rolling wave of yet another Coronavirus variant sparking global concern, vaccine mandates, booster shots and efficacy studies are dominating headlines in...
Novartis and market watchers alike have been dropping repeated hits that a sale of the Swiss drugs giant’s Sandoz-branded generic drugs arm may be closer than has been...
As the most recently documented Covid-19 variant, Omicron, continues to rapidly circle the globe – it has now been found in 57 countries and 21 US states, according to...
In response to new data published by rival Merck that downgrade earlier efficacy forecasts for its for Covid-19 oral antiviral treatment, Pfizer has announced will...
Days before news of the omicron-dubbed latest coronavirus mutant emerged, the administration of US president Joe Biden called on the courts to remove a stay on the...
